<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089206</url>
  </required_header>
  <id_info>
    <org_study_id>10049</org_study_id>
    <secondary_id>UVACC-MEL-42</secondary_id>
    <secondary_id>UVACC-24802</secondary_id>
    <nct_id>NCT00089206</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery</brief_title>
  <official_title>Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

      PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients
      with stage III or stage IV melanoma that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antitumor immune response in patients with unresectable stage III or IV
           melanoma treated with vaccine comprising multiple synthetic melanoma peptides,
           sargramostim (GM-CSF), and Montanide ISA-51.

      OUTLINE: Patients receive vaccine comprising multiple synthetic melanoma peptides,
      sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, 15, 29, 36, and 43. Patients
      undergo removal of the lymph node draining the vaccination site on day 22 to assess immune
      response.

      PROJECTED ACCRUAL: A maximum of 29 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">7</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multi-epitope melanoma peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of melanoma

               -  Unresectable stage III or IV disease

               -  Mucosal or ocular disease allowed

          -  Positive HLA-A1, -A2, or -A3 expression

        PATIENT CHARACTERISTICS:

        Age

          -  12 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 9 g/dL

        Hepatic

          -  Liver function tests ≤ 2.5 times upper limit of normal (ULN)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No New York Heart Association class III or IV heart disease

        Other

          -  Weight ≥ 100 pounds

          -  Not pregnant or nursing

          -  No other malignancy within the past 5 years except squamous cell or basal cell skin
             cancer without known metastasis, carcinoma in situ of the breast, or carcinoma in situ
             of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior vaccination with any of the peptides used in this protocol

          -  More than 1 year since prior melanoma vaccine therapy

          -  More than 4 weeks since prior immunotherapy

          -  More than 4 weeks since prior growth factors

          -  More than 4 weeks since prior allergy shots

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy

        Endocrine therapy

          -  More than 4 weeks since prior steroid therapy

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  Prior tumor resection allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center at the University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

